What the Mount Raymond acquisition means for SLAM Exploration Ltd.’s Goodwin project scale (TSXV: SXL)
Read More 5 minute read Pharma Industry News Ribo Life Science raises HKD1.8bn in Hong Kong IPO amid strong institutional support for siRNA growth strategy Ribo Life Science’s HKEX IPO raised HKD 1.83B for siRNA drug development. See how it could reshape RNA biotech investment trends in Asia. Read more. bySrinathJanuary 11, 2026